Clinical Trials/IRCT20180411039265N2

IRCT20180411039265N2

Recruiting

Phase 1

Investigation of complete-response rate of intralesional immunotherapy with Candida antigen for the treatment of molluscum contagiosum

Mashhad University of Medical Sciences0 sites40 target enrollmentTBD

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Not specified
Sponsor: Mashhad University of Medical Sciences
Enrollment: 40
Status: Recruiting
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Mashhad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

•acquisition of patient and parents' consent

Exclusion Criteria

•Pregnant or lactating women
•Violation of initial safety conditions or iatrogenic decease
•Infection with HIV1
•Increased sensitivity to Candida antigen
•Reception of any treatment in relation to molluscum during the past month

Outcomes

Primary Outcomes

Not specified

Similar Trials

Comparison of the effect of DiphenCiprone alone and DiphenCiprone with intralesional injection of platelet-rich plasma in alopecia areata

IRCT20200130046311N1Tehran University of Medical Sciences20

Determining the association of response rate to Intravitreal injection of bevacizumab and macular vessel density in patients with diabetic macular edema using optical coherence tomography angiography (OCT-A)

IRCT20220416054548N1Esfahan University of Medical Sciences70

Active, not recruiting

Phase 1/2 trial to test Nivolumab in treatment failure of Acute Myeloid Leukemia (AML) after stem cell transplantation by a allogenic donor (allo-SCT)

EUCTR2017-002194-18-DEMedical Center - University of Freiburg20

Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT)C92.0Acute myeloblastic leukaemia [AML]

DRKS00012869Ärztlicher Direktor,Universitätsklinikum Freiburg16

A nationwide questionnaire survey on late effects among Dutch childhood cancer survivors: which invitation strategy to use?

ISRCTN84711754Academic Medical Center (AMC) (Netherlands)750